復星醫藥(02196.HK)高開逾7% 小分子口服DPP-1抑制劑授權出海潛在總額達6.45億美元
復星醫藥(02196.HK)今日高開7.55%,最高暫見21.16元。現報20.66元,升6.83%,成交647.64萬股,涉資1.35億元。
復星醫藥昨日(11日)公布,控股子公司復星醫藥產業授予Expedition於許可區域(即除中國境內及港澳地區外的全球範圍)及領域開發、生產及商業化在研產品「XH-S004」的權利。根據協議,Expedition將向復星醫藥支付至多1.2億美元不可退還的首付款、開發里程碑付款,未來還將基於XH-S004於許可區域的年度淨銷售額的達成情況,由Expedition依約支付至多5.25億美元的銷售里程碑款項。
「XH-S004」為集團擁有自主知識產權的小分子口服 DPP-1抑制劑,該在研藥品的潛在適應症包括非囊性纖維化支氣管擴張症、慢性阻塞性肺疾病等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.